Ocular Therapeutix (OCUL) Successfully Appeals Patent Case Against Mati Therapeutics, Inc

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ocular Therapeutix (OCUL) Successfully Appeals Patent Case Against Mati Therapeutics, Inc

Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.

November 9, 2021 9:06 AM EST

The United States Federal Circuit Court of Appeals Affirmed Decision of the Patent Trial and Appeal Board that Mati Therapeutics Patent is Invalid

Mati Therapeutics Had Previously Alleged that DEXTENZA® Was Infringing Patent in Question

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated a patent... More